

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED**

**精優藥業控股有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 00858)**

### **ANNOUNCEMENT**

Reference is made to the announcement of Extrawell Pharmaceutical Holdings Limited (the “**Company**” which, together with its subsidiaries, the “**Group**”) dated 6 February 2013 that trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been halted with effect from 9:00 a.m. on 6 February 2013 pending the release of an announcement in relation to inside information of the Company.

On 23 February 2013, the Company entered into an agreement relating to the acquisition (the “**Acquisition**”) of the remaining minority interests in Smart Ascent Limited, a non-wholly owned subsidiary of the Company and the holding company for the Group’s oral insulin operations. The Acquisition constitutes a connected and major transaction of the Company. An announcement setting out details of the Acquisition will be published as soon as practicable.

Trading in the shares of the Company will remain suspended until publication of the announcement in relation to the Acquisition.

By order of the Board  
**Extrawell Pharmaceutical Holdings Limited**  
**Xie Yi**  
*Director*

Hong Kong, 23 February 2013

*As at the date of this announcement, the executive directors are Dr. Mao Yumin, Dr. Xie Yi, Dr. Lou Yi and Ms. Wong Sau Kuen and the independent non-executive directors are Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song.*

\* *For identification purpose only*